Krishnan Suma sold $414K of KRYS
Krishnan Suma (President, R&D) sold 1,348 shares of Krystal Biotech, Inc. (KRYS) at $307.09 ($0.41M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure can influence short-term sentiment, but the 10b5-1 designation generally lowers the probability that the sale conveys new negative information.
Market read
A single insider sale under a pre-arranged plan is typically a low-signal event for trading; any price reaction is likely modest.
What to watch
Traders may over-weight insider sales; the more actionable signal would be whether multiple insiders sell/buy around the same time or whether the company has concurrent fundamental news (not present here).
Background
The article is an SEC Form 4 insider transaction disclosure for Krystal Biotech, reporting an open-market sale by an officer/director/10% owner under a Rule 10b5-1 plan.
Ticker impact
Krystal Biotech insider Krishnan Suma (President, R&D; 10% owner) sold $413,963 of KRYS shares via a 10b5-1 plan disclosed on Form 4.
Likely limited/short-lived impact; any reaction should be muted given the disclosed 10b5-1 plan.
The filing provides a concrete transaction datapoint (size, price, date) but explicitly notes a pre-arranged 10b5-1 plan, which typically dampens interpretive value versus discretionary sales.
Market effects
Minimal—this is company-specific insider activity with no sector-wide catalyst described.
None indicated beyond KRYS equity.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the SEC Form 4 insider transaction disclosure (KRYS).
- insiderKrishnan Suma
President, R&D; officer/director/10% owner who sold 1,348 shares for ~$413,964 under a 10b5-1 plan.
